Sternberg, C.N.

patient cancer prostate prostate cancer trial treatment therapy study survival disease metastatic docetaxel androgen chemotherapy phase oncol urology oncology group hormone european level result androgen deprivation therapy member deprivation randomized progression radiation panel factor university response psa level radiotherapy combination tax 327 study hormone-refractory prostate cancer prostatectomy bleomycin castration prostate-speci fic antigen metastase oncology /hematology 68 3 bep regimen hormone therapy cisplatin hormone-refractory effect androgen deprivation evidence hospital surgery benefit lhrh-a receptor toxicity approach score prednisone clinicaltrials.gov identifier analysis society bicalutamide mortality difference metastatic disease psadt stage gleason etoposide month randomised placebo tumor oncologist metastatic crpc signi carcinoma